Oxford Cann Share News (OCTP)

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Pod Point cuts outlook; CVS Group buys in Australia

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Oxford Cannabinoid expands into oncology; discovers tumour treatment

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC said on Monday that it was formally expanding its research & development strategy into oncology, having discovered a potential cannabinoid-based treatment for tumours.

IN BRIEF: Oxford Cannabinoid appoints Nodenza's Tim Corn as new CMO

Oxford Cannabinoid Technologies Holdings PLC - holding company of Oxford Cannabinoid Technologies Ltd, a pharmaceutical group developing prescription cannabinoid medicines - Appoints Tim Corn as new chief medical officer, effective immediately.

IN BRIEF: Oxford Cannabinoid clinical trial application approved

Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Announces that the Medicines & Healthcare Products Regulatory Agency and the Wales Research Ethics Committee have approved the company's combined Phase I clinical trial application for OCTP's lead drug candidate, OCT461201. This Phase I first-in-human clinical trial is being conducted in the UK in healthy volunteers, with a single ascending dose protocol. Participant enrolment will begin immediately, and the trial is expected to be completed during the third quarter. The trial is being funded entirely from OCTP's existing resources.

IN BRIEF: Oxford Cannabinoid shares up as Sowemimo-Coker named CEO

Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Names Clarissa Sowemimo-Coker as permanent chief executive officer, effective immediately. She was named interim CEO in December, after having joined the firm over four years ago. Additionally, says its subsidiary Oxford Cannabinoid Technologies Ltd has renewed its Home Office licence, which permits OCT to supply Schedule 1 drugs for research purposes. Adds that progress towards the commencement of phase 1 clinical trial for its lead drug candidate, OCT461201, continues.

Oxford Cannabinoid interim loss nearly doubles as research costs surge

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Monday reported a widened half-year loss as research costs ballooned.

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Arkle finds pegmatites; Apollon win license deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Oxford Cannabinoid submits trials application for agonist

Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Says that on Wednesday, it submitted a combined clinical trials application to the UK Medicines & Healthcare products Regulatory Agency and the Wales Research Ethics Committee 2 for its lead programme OCT461201.

IN BRIEF: Oxford Cannabinoid CEO steps down to pursue other interests

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical firm developing prescription cannabinoid medicines - Announces that Chief Executive John Lucas has decided to step down from his role "in order to pursue other business interests."

IN BRIEF: Oxford Cannabinoid hires Smalley as new finance director

Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Hires Paul Smalley as the new group finance director, effective from today. Says he will succeed Karen Lowe, who pans to stepd down from the board and leave the firm on October 31.

UK shareholder meetings calendar - next 7 days

Oxford Cannabinoid to review budget; finance director steps down

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Friday announced the reallocation of its existing budget, in the face of growing market uncertainty and a challenging macro-economic outlook.

SMALL-CAP WINNERS & LOSERS: Oxford Cannabinoid sinks on trial delay

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.